Graves Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019 On 21stNovember 2014
Summary The industry analysis specialist, has released its new report, “Graves’ Disease Therapeutics Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global Graves Disease Therapeutics market. The report identifies the key trends shaping and driving the global Graves Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graves Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-graves-disease-therapeutics-pipeline-assessment-and-marketforecast-135176 Scope The report provides information on the key drivers and challenges of the Graves Disease Therapeutics market. Its scope includes Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graves Disease Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Graves Disease Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Graves Disease Therapeutics market. - Analysis of key recent licensing and partnership agreements in Graves Disease Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Graves Disease Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Graves Disease Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- What’s the next big thing in the global Graves Disease Therapeutics market landscape? – Identify, understand and capitalize.
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Introduction 6 2.1 Overview 6 2.1.1 Biosynthesis of Thyroid Hormones 6 2.2 Epidemiology 7 2.3 Etiology 8 2.4 Risk Factors 9 2.5 Signs and Symptoms 9 2.6 Diagnosis 11 2.6.1 Laboratory Tests 11 2.6.2 Imaging Tests 12 2.7 Treatment 12 2.7.1 Antithyroid drugs 12 2.7.2 Radioactive Iodine (RAI) Therapy 13 2.7.3 Thyroid Surgery 13 2.7.4 Treatment for Graves’ Ophthalmology 13 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.8 GlobalData Pipeline Report Guidance 14 3 Graves’ Disease Therapeutics - Market Characterization 15 3.1 Major Markets, Market Size (2006 - 2011) 15 3.2 Major Markets, Market Forecast (2011 - 2019) 17 3.3 US Market Size (2006 - 2011) 19 3.4 US Market Forecast (2011 - 2019) 20 3.5 UK Market Size (2006 - 2011) 21 3.6 UK Market Forecast (2011 - 2019) 22 3.7 Germany Market Size (2006 - 2011) 23 3.8 Germany Market Forecast (2011 - 2019) 24 3.9 Italy Market Size (2006 - 2011) 25 3.10 Italy Market Forecast (2011 - 2019) 26 3.11 France Market Size (2006 - 2011) 27 3.12 France Market Forecast (2011 - 2019) 28 3.13 Spain Market Size (2006 - 2011) 29 3.14 Spain Market Forecast (2011 - 2019) 30 3.15 Japan Market Size (2006 - 2011) 31 3.16 Japan Market Forecast (2011 - 2019) 32 3.17 Drivers and Barriers for Graves’ Disease Therapeutic Market 33 3.17.1 Drivers for the Graves’ Disease Market 33 3.17.2 Barriers for Graves’ disease Market 33 3.18 Opportunity and Unmet Need 35 3.19 Key Takeaway 35 4 Graves’ Disease Market - Competitive Assessment 36 4.1 Overview 36 4.1.1 Strategic Competitor Assessment 36 4.2 Graves’ Disease Marketed Products Profile 37 4.2.1 Antithyroid drugs 37 4.2.2 Radioactive Iodine Therapy 38 4.2.3 Beta Blockers 38 4.3 Key Takeaway 38 5 Graves’ Disease - Pipeline Assessment 39 5.1 Overview 39 5.2 Strategic Pipeline Assessment 39 5.3 Graves’ Disease Pipeline Analysis - Pipeline by Clinical Phase of Development 40 5.3.1 Graves’ Disease Therapeutics - Phase II/III Clinical Pipeline 40 5.3.2 Graves’ Disease Therapeutics - Phase I Clinical Pipeline 41 5.3.3 Graves’ disease Therapeutics - Discovery Pipeline 41 5.4 Graves’ Disease Pipeline by Mechanism of Action 41 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.5 Graves’ Disease Technology Trends Analytical Framework 42 5.6 Molecule Profile for Drug under Late-stage Clinical Development 43 5.6.1 Rituxan/MabThera (rituximab) 43 5.7 Key Takeaway 43 6 Graves’ Disease Therapeutics - Clinical Trials Mapping 44 6.1 Clinical Trials Mapping by Region/Country 44 6.2 Clinical Trials Mapping by Phase 45 6.3 Clinical Trials Mapping by Trial Status 46 6.4 Clinical Trials Mapping by Overall Sponsors 47 6.5 Clinical Trials Mapping by Sponsors 48 7 Graves’ Disease Therapeutics - Implications for Future Competition 49 7.1 Future Market Competition Scenario 49 8 Global Graves’ Disease Therapeutics - Future Players in The Market 50 8.1 Introduction 50 8.2 GlaxoSmithKline 50 8.2.1 Company Overview 50 8.2.2 Financial Performance: 50 8.2.3 Business Description 51 8.3 Apitope International NV 52 8.3.1 Company Overview 52 9 Global Graves’ Disease Therapeutics Appendix 53 9.1 Definitions 53 9.2 Acronyms 53 9.3 Methodology 54 9.3.1 Coverage 54 9.3.2 Secondary Research 54 9.3.3 Forecasting 54 9.3.4 Primary Research 56 9.3.5 Expert Panel Validation 57 9.4 Contact Us 57 9.5 Disclaimer 57 9.6 Sources 57
List Of Tables Table 1: Prevalence of Prevalence, 2011 7 Table 2: Graves’ Disease Therapeutics, Global, Market Revenue ($m), 2006 - 2011 15 Table 3: Graves’ Disease Therapeutics, Global, Revenue Forecasts ($m), 2011 - 2019 17 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 4: Graves’ Disease Therapeutics, The US, Market Historical Revenue ($m), 2006 - 2011 19 Table 5: Graves’ Disease Therapeutics, The US, Revenue Forecasts ($m), 2011 - 2019 20 Table 6: Graves’ Disease Therapeutics, The UK, Market Historical Revenue ($m), 2006 - 2011 21 Table 7: Graves’ Disease Therapeutics, The UK, Revenue Forecasts ($m), 2011 - 2019 22 Table 8: Graves’ Disease Therapeutics, Germany, Market Revenue ($m), 2006 - 2011 23 Table 9: Graves’ Disease Therapeutics, Germany, Revenue Forecasts ($m), 2011 - 2019 24 Table 10: Graves’ Disease Therapeutics, Italy, Market Revenue ($m), 2006 - 2011 25 Table 11: Graves’ Disease Therapeutics, Italy, Revenue Forecasts ($m), 2011 - 2019 26 Table 12: Graves’ Disease Therapeutics, France, Market Revenue ($m), 2006 - 2011 27 Table 13: Graves’ Disease Therapeutics, France, Revenue Forecasts ($m), 2011 - 2019 28 Table 14: Graves’ Disease Therapeutics, Spain, Market Revenue ($m), 2006 - 2011 29 Table 15: Graves’ Disease Therapeutics, Spain, Revenue Forecasts ($m), 2011 - 2019 30 Table 16: Graves’ Disease Therapeutics, Japan, Market Revenue ($m), 2006 - 2011 31 Table 17: Graves’ Disease Therapeutics, Japan, Revenue Forecasts ($m), 2011 - 2019 32 Table 18: Graves’ Disease Therapeutics - Phase II/III Clinical Pipeline, 2011 40 Table 19: Graves’ Disease Therapeutics - Phase I Clinical Pipeline, 2011 41 Table 20: Graves’ Disease Therapeutics - Discovery Pipeline, 2011 41 Table 21: Graves’ Disease Clinical Trials by Region - Number, 2011 44 Table 22: Graves’ Disease Clinical Trials by Phase, 2011 45 Table 23: Graves’ Disease Clinical Trials by Status , 2011 46 Table 24: Graves’ Disease Clinical Trials by Overall Sponsors, 2011 47 Table 25: Graves’ Disease Clinical Trials by Sponsors, 2011 48
List Of Figures Figure 1: Pathophysiology of Graves’ Disease 8 Figure 2: Different Forms of Pretibial Myxedema Seen in Patients of Graves’ Disease 10 Figure 3: Graves’ Ophthalmology 10 Figure 4: Graves’ Disease Therapeutics, Global, Market Revenue ($m), 2006 - 2011 15 Figure 5: Graves’ Disease Therapeutics, Market Share (%), 2011 16 Figure 6: Graves’ Disease Therapeutics, Global, Revenue Forecasts ($m), 2011 - 2019 17 Figure 7: Graves’ Disease Therapeutics, Forecast Market Share (%), 2019 18 Figure 8: Graves’ Disease Therapeutics, The US, Market Revenue ($m), 2006 - 2011 19 Figure 9: Graves’ Disease Therapeutics, The US, Revenue Forecasts ($m), 2011 - 2019 20 Figure 10: Graves’ Disease Therapeutics, The UK, Market Revenue ($m), 2006 - 2011 21 Figure 11: Graves’ Disease Therapeutics, The UK, Revenue Forecasts ($m), 2011 - 2019 22 Figure 12: Graves’ Disease Therapeutics, Germany, Market Revenue ($m), 2006 - 2011 23 Figure 13: Graves’ Disease Therapeutics, Germany, Revenue Forecasts ($m), 2011 - 2019 24 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 14: Graves’ Disease Therapeutics, Italy, Market Revenue ($m), 2006 - 2011 25 Figure 15: Graves’ Disease Therapeutics, Italy, Revenue Forecasts ($m), 2011 - 2019 26 Figure 16: Graves’ Disease Therapeutics, France, Market Revenue ($m), 2006 - 2011 27 Figure 17: Graves’ Disease Therapeutics, France, Revenue Forecasts ($m), 2011 - 2019 28 Figure 18: Graves’ Disease Therapeutics, Spain, Market Revenue ($m), 2006 - 2011 29 Figure 19: Graves’ Disease Therapeutics, Spain, Revenue Forecasts ($m), 2011 - 2019 30 Figure 20: Graves’ Disease Therapeutics, Japan, Market Revenue ($m), 2006 - 2011 31 Figure 21: Graves’ Disease Therapeutics, Japan, Revenue Forecasts ($m), 2011 - 2019 32 Figure 22: Graves’ Disease Therapeutic Market - Drivers and Barriers 34 Figure 23: Opportunity and Unmet Need in the Graves’ Disease Therapeutic Market 35 Figure 24: Strategic Competitor Assessment of Marketed Products for Graves’ Disease, 2011 37 Figure 25: Pipeline Products by Phase of Clinical Development, 2011 39 Figure 26: Pipeline Products by indication 40 Figure 27: Graves’ Disease Therapeutics Pipeline by Phase of Clinical Development, 2011 40 Figure 28: Graves’ Disease Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011 41 Figure 29: Technology Trends Analytical Framework of The Graves’ Disease Pipeline, 2011 42 Figure 30: Technology Trends Analytical Framework of The Graves’ Disease Pipeline Description, 2011 42 Figure 31: Graves’ Disease Clinical Trials by Region, 2011 44 Figure 32: Graves’ Disease Clinical Trials by Phase, 2011 45 Figure 33: Graves’ Disease Clinical Trials by Status, 2011 46 Figure 34: Graves’ Disease Clinical Trials by Sponsors, 2011 47 Figure 35: Graves’ Disease Clinical Trials by Prominent Sponsors, 2011 48 Figure 36: Implications for Future Market Competition in the Graves’ Disease Market, 2011 49 Figure 37: Graves’ Disease Therapeutics, Clinical Pipeline by Company, 2011 50 Figure 38: GlobalData Market Forecasting Model 56
Report Price: Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Related Reports: Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Waldenstrms Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Cushings Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Pompe Disease (GAA Deficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Sarcoidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gauchers Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Graves Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-graves-diseasetherapeutics-pipeline-assessment-and-market-forecast-135176
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/